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ABSTRACT
Hepatitis C is a major cause of chronic liver disease worldwide. There is a significant 
variation in the prevalence of hepatitis C virus (HCV) infection, according to the geo-
graphic region investigated. These discrepancies reflect not only distinct epidemiological 
characteristics among populations, but also differences in methodologies. Although data 
are scarce, estimates indicate that, in Brazil, the prevalence of HCV infection is inter-
mediate, ranging from 1% to 2%. The most important risk factors for HCV infection 
include intravenous drug use, blood product transfusion, organ transplantation, hemo-
dialysis, occupational exposure, sexual transmission, and vertical transmission. Due to 
lack of vaccine or effective post-exposure prophylaxis, the main focus of prevention is 
to recognize and control these risk factors. In this article, we review the literature on the 
prevalence of HCV infection, particularly in Brazil. In addition, we discuss the pattern 
of HCV infection according to the age groups and risk factors. 
Keywords: Hepatitis C; epidemiology; infectious disease transmission; prevalence; 
risk factors.
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Figure 1 – Estimated prevalence of HCV infection according 
to geographic area (adapted from Perz et al.8).
Figure 2 – Prevalence of anti-HCV positivity per age group 
(see text) (adapted from Wasley & Alter4).
INTRODUCTION
Since the isolation of complementary DNA of hepatitis C 
virus (HCV) by Choo et al.1, in 1989,hepatitis C has been 
recognized as one of the main causes of chronic liver dis-
ease worldwide.
Prevention and control of hepatitis C depend on a 
complex evaluation of global distribution of HCV infec-
tion, determination of its risk factors, and assessment of 
factors that accelerate disease progression. Moreover, due 
to the lack of a vaccine or some form of post-exposure 
prophylaxis, an accurate epidemiological assessment to 
plan primary prevention actions in any given population 
is essential2.
SEARCH CRITERIA
An exhaustive review of the literature on the epidemi-
ology of hepatitis C was carried out. The Medline and 
Scielo databank were searched using the following com-
bination of words: hepatitis C; epidemiology; prevalence; 
risk factors; and transmission. Studies or case reports, 
correspondences, commentaries, or non-published stud-
ies were not included.
GLOBAL PREVALENCE
One of the ways of estimating the prevalence of hepatitis 
C is through seroprevalence studies performed in blood 
donors. However, since this is a population with specific 
characteristics, such studies may not accurately represent 
the real prevalence of disease. This discrepancy has been 
demonstrated in the North American population, which 
in the 1990s had an estimated prevalence of HCV infec-
tion of 0.6% in studies of blood donors and 1.8% in general 
population3. Other investigations, such as those in patients 
with chronic liver disease, should also be carefully inter-
preted, since those individuals do not adequately represent 
the total population of a specific area. Although popula-
tional studies with representative samples of one or more 
communities are more appropriate, they are more complex 
and expensive and may not be accomplished in most re-
gions of the world. Even with these considerations, esti-
mates indicate a global prevalence around 2% to 3%, i.e., 
between 123 million and 170 million people with HCV 
infection worldwide2,4-7.
 Although hepatitis C is considered endemic world-
wide, there is a high degree of geographical variation in 
its distribution2,4-7. In many countries data are missing, 
and estimates are based on adjusted means for a specific 
region. Figure 1 shows the estimated prevalence of HCV 
infection according to geographic region.
The prevalence of HCV infection is low, in the United 
Kingdom, Scandinavia (0.01% to 0.1%), Americas, West-
ern Europe, Australia, and South Africa (0.2% to 0.5%)8. 
Intermediate prevalence is seen in Eastern Europe, Medi-
terranean, Middle East, and India8. Other countries with 
intermediate prevalence include Brazil, Eastern Europe, 
parts of Africa, and Asia4,8. Egypt has a high prevalence 
of HCV infection (17% to 26%). besides Hubei, Mongolia, 
and Pakistan4,6.
There is only a limited number of studies relating the 
prevalence of HCV infection at different ages, and they 
show not only regional but temporal variations that reflect 
times of HCV transmission increased risk in each region6. 
In these works, at least three distinct epidemiological pat-
terns are observed (Figure 2). The first pattern occurs in 
countries like USA and Australia with the highest preva-
lence of HCV in the population between 30 and 39 years 
of age and lower prevalence in those aged below 20 and 
above 50 years4. In this case, it has been hypothesized that 
higher rates of transmission had, in the recent past, affect-
ed the 10 to 30 years age group4. The second pattern, seen 
in Turkey, Spain, Italy, Japan, and China, the majority of 
those infected are over the age of 50, which might indicate 
a greater risk of infection in the distant past, roughly be-
tween 40 and 60 years4. The third pattern, seen in Egypt, 
in which an increase in the number of cases with age and, 
at the same time, a large number of cases in all age groups, 
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Figure 3 – Prevalence of anti-HCV  positivity in blood donors 
in different Brazilian states10.
indicates an increased risk of transmission in the distant 
past, which is continuously maintained2,7. Identification 
of those prevalence patterns of HCV infection in different 
age groups probably shows the epidemiologic characteris-
tics specific to each region. Knowledge of the prevalence 
pattern in different countries and places might allow great-
er effectiveness of HCV infection detection and control.
PREVALENCE IN BRAZIL
Brazil is a continental country and, therefore, with large 
demographic, social, and cultural variations among its dif-
ferent regions. For this reason, studies evaluating the prev-
alence of HCV in Brazil are scarce and not precise, usually 
encompassing restrict geographic areas or specific popu-
lations, such as blood donors9. Reports of several studies 
have contradictory information, suggesting the need for 
studies with more appropriate methodology.
A survey by the Brazilian Society of Hepatology 
showed that out of 1,173,406 blood donors evaluated, 
14,527 (1.23%) were positive for anti-HCV. Figure 3 shows 
the spatial distribution of anti-HCV positivity per state10. 
The higher prevalence rates were observed in Northern 
states (2.12%)10. On the other hand, the Southern region 
showed low prevalence of anti-HCV positivity (0.65%). 
Midwestern, Northeast, and Southeast regions showed in-
termediate rates (1.04%, 1.19%, and 1.43%, respectively)10. 
However, as discussed earlier, the use of a specific group, 
such as blood donors, limits extrapolation of these esti-
mates for general population.
In 1998, a populational study by Focaccia et al.11, re-
ported a prevalence of anti-HCV positivity of 1.42% in 
1049 residents of São Paulo county.11 Higher prevalence 
was observed in individuals over 30 years of age, with 
the peak of 3.8% seen in the 50 to 59-year age group11. 
As mentioned before, the greater prevalence of hepatitis C 
observed aer the age of 50 suggests infection in the dis-
tant past and a gradual dislocation among age groups, with 
a tendency to concentrate most cases among the elderly.
RISK AND TRANSMISSION FACTORS
The investigation of the risk factors for HCV infection 
can be done by prospective or retrospective studies, and 
several studies indicate as main risk factors: transfusion of 
blood and blood products from non-tested blood donors; 
organ transplantation from infected donors; IV drug use; 
therapy with injected drugs with contaminated (or not 
safe) equipment; hemodialysis; occupational exposure to 
blood; perinatal infection; and sexual transmission12-16. 
Moreover, due to the great variety of human activities 
with potential exposure to blood, several possible biologic 
transmission models exist, such as tattoo, piercing, barber 
shop, scarification rituals, circumcision, and acupuncture.
Among the different risk factors, the ones described 
most oen in literature include blood transfusion, IV drug 
use, and invasive therapies with contaminated (or unsafe) 
equipment12,13. However, a significant variation on the im-
portance of each of those factors in disease transmission 
was observed over time in each region7.
TRANSFUSION OF BLOOD PRODUCTS
Transfusion of blood and blood products from non-
tested donors is considered the most important type 
of transmission. However, aer randomization of pre-
donation screening processes, a significant reduction in 
HCV transmission through blood products transfusion 
was observed17. It has been estimated that, between 1960 
and 1991, 5% to 15% of blood product receptors were 
infected with HCV and that, currently, aer adoption of 
screening tests, the risk of infection from blood transfu-
sion is around 0.001% per unit of blood transfused18. De-
spite this significant reduction observed in the last years, 
a study performed in the largest blood bank in Santa 
Catarina demonstrated that the possibility of contamina-
tion by HCV is still in the other of one to 13.721 units of 
blood transfused19, which is at least 10 times higher than 
that observed in developed countries19.
INTRAVENOUS DRUG USE
Aer reduction in HCV transmission by blood products 
transfusion, sharing contaminated material by IV drug 
users became the greatest risk factor for transmission of 
disease. Intravenous drug use was one of the main types of 
HCV transmission in the last 40 years in countries like the 
United States and Australia12,20, being currently the main 
risk factor in developed countries12,20. In these countries, 
IV drug use is responsible for approximately 70% to 80% 
of HCV contaminations in the last 30 years12,20.
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A study by Thorpe et al. demonstrated that the preva-
lence of HCV infection among IV drug users has varied 
from 70% to 90%21, and it seems to increase with the time 
of use22,23. However, some studies have demonstrated that 
even the recent users (less than six months) can present 
rates higher than 75%21. In Brazil, statistics are scarce. 
However, in a study that evaluated the prevalence of anti-
HCV in IV drug users in the city of Santos, showed a rate 
of 75%, comparable to rates reported by most countries.
MEDICAL PROCEDURES AND NOSOCOMIAL EXPOSURE
Injectable therapies with contaminated (or unsafe) equip-
ment represent another possible form of HCV transmis-
sion25. Despite the scarcity of reliable data, it has been 
estimated that approximately two million individuals are in-
fected annually by this route25. In developing countries, the 
supply of sterilized material can be inadequate or nonexis-
tent. Moreover, outside of medical centers, injectable thera-
pies might be performed by untrained individuals; there-
fore, throughout life, a person can received several injections 
with contaminated material, increasing significantly the 
accumulate risk of HCV infection25. In Egypt, the country 
with the higher prevalence of hepatitis C in the world, most 
individuals were contaminated by reusing glass syringes 
during national campaigns to treat schistosomiasis between 
1960 and 198726. Similarly, in India, the prevalence of HCV 
among patients who received several injectable treatments 
for kala-azar is 31.1%, which is significantly higher than the 
prevalence observed in general population27.
Patients on hemodialysis have higher prevalence of 
HCV infection5, ranging from 19% to 47.2%10. Among 
the factors associated with higher HCV infection rates in 
hemodialysis patients are the time of dialysis and demo-
graphic region6, Hepatitis C virus transmission among 
hemodialysis patients is mainly nosocomial. Possible risk 
factors include sharing hemodialysis equipment and in-
struments and the lack of adhesion to standard precaution 
measures and equipment sterilization28.
SOLID ORGAN TRANSPLANTATION
The estimated prevalence of HCV infection in organ 
transplant recipients is complicated by the influence of 
immunosuppression on the accuracy of serological tests 
commonly used. The prevalence of anti-HCV in organ do-
nors, according to studies in cadavers, ranges from 4.2% to 
5.1%, depending on the test used29. Recipients from anti-
HCV positive donors seem to have elevated seroconver-
sion rates; in a study with patients who received kidney 
gras, 35% of recipients from anti-HCV positive donors 
developed post-transplantation liver disease, and 74% 
showed evidence of viremia30. Despite these data, evidence 
is still limited and there is a clear need for further stud-
ies to evaluate the impact of organ transplantation in the 
prevalence of HCV.
OCCUPATIONAL EXPOSURE
Needle sticks accidents with percutaneous inoculation is 
a well-documented HCV transmission, with seroconver-
sion rates affer a single percutaneous exposure to known 
infected material ranging from 3% to 10%31,32. For this rea-
son, several authors have evaluated the prevalence of HCV 
in health care professionals. Studies in the early 1990 indi-
cated that the prevalence of HCV infection was three times 
higher in health care workers than among other profes-
sionals31. However, other studies indicated a prevalence of 
0.7% to 2% among health care workers, which is similar to 
that of general population. The prevalence of HCV among 
dentists was 0.7% to 1.7%, and, among oral surgeons, the 
prevalence was 2% to 9.3%38,39. A study with orthopedic 
surgeons who denied the presence of non-occupational 
risk factors showed a prevalence of less than 1%40. Despite 
these conflicting data, occupational exposure remains a 
potential risk factor for HCV infection, especially due to 
the absence of effective post-exposure prophylactic mea-
sures in this context.
VERTICAL TRANSMISSION
Rates of vertical HCV transmission range from 0% to 
20%, with a mean of approximately 5% in most stud-
ies41-43. Risk factors for vertical transmission include el-
evated maternal viral load, prolonged labor, internal fetal 
monitoring, and HIV-HCV coinfection15,44. Coinfected 
mothers were 3.8 times more prone to transmit HCV to 
the fetus42. Breast feeding did not contribute significantly 
to HCV transmission43.
SEXUAL TRANSMISSION
 The risk associated with sexually transmitted HCV is not 
yet fully understood5, and this risk factor is one of the most 
controversial in the epidemiology of hepatitis C among 
different results in different studies45,46. A higher preva-
lence of HCV infection has been observed among patients 
treated in clinics specialized in sexually transmitted dis-
eases, among prostitutes and their partners and among 
patients with HIV-HCV coinfection47-52,54.
Other risk factors related to sexual behavior seem to 
contribute for the higher transmission rate of HCV, in-
cluding: higher number of sexual partners46, presence of 
other sexually transmitted diseases, such as trichomonia-
sis, HIV/AIDS, syphilis, and Chlamydia,47,48 low use of 
condoms46,53, traumatic sexual experience46,50,53, and male 
homosexuality46,47,53-55. Additionally, male-female trans-
mission seem to be easier than female-male transmission56.
Despite this evidence, studies with monogamous 
couples demonstrated low risk of sexual transmission55. 
Moreover, the possibility of intrafamilial transmission by 
sharing personal hygiene material or occasional exposure 
to contaminated blood hinders interpretation of studies 
assessing sexual transmission of HCV57,58.
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CONCLUSION
Currently, hepatitis C is one of the most common causes 
of chronic liver disease worldwide. Evidence suggests that 
most of the cases in Brazil affect individuals over 50 years 
of age. However, with the significant reduction in blood 
products transfusion-related transmission, the role of 
sharing contaminated material by IV drug users has been 
increasing and it can be responsible for a significant num-
ber of cases, especially among youngsters. Studies with 
proper methodology in order to establish the prevalence 
of hepatitis C as well as the risk factors for contracting 
the disease in the Brazilian population are needed to cor-
rectly implement control measures and resource allocation 
against HCV infection.
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